Vistagen to Present Exploratory Safety and Efficacy Data for Fasedienol (PH94B) from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting

Vistagen to Present Exploratory Safety and Efficacy Data for Fasedienol (PH94B) from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting

Last Hour Poster Presentation Highlights Data on Long-Term Open-Label Treatment of As-Needed Intranasal Phasedienol Administrations in a Real-World Setting SOUTH SAN FRANCISCO, California, May 30, 2023–(BUSINESS WIRE)–Vistagen (Nasdaq: VTGN), an advanced clinical-stage biopharmaceutical company aiming to transform the treatment landscape for people living with anxiety, depression, and other central nervous system (CNS) disorders, today announced … Read more